Our site may be slower due to heavy traffic from automated "bots" and AI crawlers. We're working to fix this.

Roly Gosling, PhD, MS, MD

Title(s)Professor, Epidemiology & Biostatistics
SchoolSchool of Medicine
Address3333 California Street, #001
San Francisco CA 94118
ORCID ORCID Icon0000-0001-6291-0024 Additional info
vCardDownload vCard

    Collapse Overview 
    Collapse overview
    The malaria elimination initiative is focussed on supporting countries to succeed in elimination of both falciparum and vivax malaria. We have a broad range of activities from desk based research producing advocacy and summary materials to highlight the substantial progress of malaria control and elimination world wide, to field based research exploring active surveillance strategies, efficacy of drug based transmission interventions, costing studies of elimination programs and more qualitative research such as case studies. The program also supports countries by supporting regional networks of countries to eliminate malaria (the Asia Pacific Malaria Elimination Network, APMEN and the Eliminating 8, E8 in southern Africa).

    Dr Gosling is based in Namibia until 2020.

    We do have opportunities to send students to support field research studies.
    Collapse Global Health Equity

    Collapse Featured Content 
    Collapse Collaboration Interests

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help. to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    Altmetrics Details PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Tailoring malaria control interventions to suit local context: codesign of perennial malaria chemoprevention (PMC) programmes through the Plus Project. BMJ Glob Health. 2025 Oct 05; 10(10). Center M, McGirr AL, Skjefte M, Ekobika LC, Bahibo H, Nhantumbo E, Wakpo B, Ogouyemi Hounto A, Yah Kokrasset C, Candrinho B, Malhotra K, Clarke SE, Gosling RD, Kouakou J. PMID: 41052818; PMCID: PMC12506191.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    2. Understanding stakeholder perspectives on integrating and sustaining a vertical HIV prevention programme into routine health services in Zimbabwe: a qualitative study. BMJ Glob Health. 2025 Aug 11; 10(8). Chung AM, Murungu J, Case P, Chitapi P, Chikodzore R, Gosling J, Xaba S, Ncube G, Mugurungi O, Kunaka P, Prata N, Gosling RD, Bertozzi SM, Auerswald C. PMID: 40789715; PMCID: PMC12352186.
      View in: PubMed   Mentions:    Fields:    Translation:HumansPHPublic Health
    3. Targeting malaria in high-risk populations in low endemic regions in northern Namibia: a quasi-experimental controlled trial to reduce malaria in seasonal agricultural workers and cattle herders. BMJ Glob Health. 2025 Feb 17; 10(2). Smith JL, Ntuku H, Rerolle F, Burke AM, Mwema T, Turcios K, Uusiku P, Haikali JK, Lifasi M, Smith-Gueye C, Vajda E, Jacobson JO, Greenhouse B, Gosling R, Bennett A, Mumbengegwi DR. PMID: 39961693; PMCID: PMC11836845.
      View in: PubMed   Mentions:    Fields:    Translation:HumansAnimalsPHPublic Health
    4. Effect of mass drug administration on malaria incidence in southeast Senegal during 2020-22: a two-arm, open-label, cluster-randomised controlled trial. Lancet Infect Dis. 2025 Jun; 25(6):656-667. Ba EKC, Roh ME, Diallo A, Gadiaga T, Seck A, Thiam S, Fogelson A, Gaye S, Diallo I, Lo AC, Diouf E, Ba OG, Gueye AB, Wu X, Milligan P, Kibuka T, Hama M, Eckert E, Thwing J, Bennett A, Gosling R, Hwang J, Sene D, Ba F, Cissé B, Sturm-Ramirez K, Hsiang MS, Ndiaye JL. PMID: 39799956; PMCID: PMC12103279.
      View in: PubMed   Mentions: 3     Fields:    Translation:HumansAnimalsPHPublic Health
    5. Regional action needed to halt antimalarial drug resistance in Africa. Lancet. 2025 Jan 04; 405(10472):7-10. Martinez-Vega R, Ishengoma DS, Gosling R, Rosenthal PJ, Dondorp A, Barnes KI, Nsanzabana C, Djimde AA, Ochola-Oyier LI, Tibenderana J, Chimumbwa J, Golassa L, Kapologwe NA, Mbacham WF, Kamya MR, Fidock DA, Komatsu R, von Seidlein L, Dhorda M. PMID: 39674185; PMCID: PMC11838165.
      View in: PubMed   Mentions: 4     Fields:    
    6. Post-treatment duration of positivity for standard and ultra-sensitive Plasmodium falciparum antigen-based rapid diagnostic tests, a cohort study from a low-endemic setting in Namibia. EBioMedicine. 2025 Jan; 111:105489. Ntuku H, Whittemore B, Dausab L, Jang IK, Golden A, Sheahan W, Wu X, Slater H, Domingo GJ, Das S, Duarte E, Eloff L, Bousema T, Lanke K, Gueye CS, Prach LM, Raman J, Uusiku P, Katokele S, Gosling R, Greenhouse B, Mumbengegwi D, Hsiang MS. PMID: 39657364; PMCID: PMC11683224.
      View in: PubMed   Mentions: 1     Fields:    Translation:HumansAnimals
    7. Extension of efficacy range for targeted malaria-elimination interventions due to spillover effects. Nat Med. 2024 Oct; 30(10):2813-2820. Benjamin-Chung J, Li H, Nguyen A, Barratt Heitmann G, Bennett A, Ntuku H, Prach LM, Tambo M, Wu L, Drakeley C, Gosling R, Mumbengegwi D, Kleinschmidt I, Smith JL, Hubbard A, van der Laan M, Hsiang MS. PMID: 38965434; PMCID: PMC11483210.
      View in: PubMed   Mentions: 4     Fields:    Translation:HumansAnimalsPHPublic Health
    8. Urgent action is needed to confront artemisinin partial resistance in African malaria parasites. Nat Med. 2024 Jul; 30(7):1807-1808. Ishengoma DS, Gosling R, Martinez-Vega R, Beshir KB, Bailey JA, Chimumbwa J, Sutherland C, Conrad MD, Tadesse FG, Juliano JJ, Kamya MR, Mbacham WF, Ménard D, Rosenthal PJ, Raman J, Tatarsky A, Tessema SK, Fidock DA, Djimde AA. PMID: 38710833.
      View in: PubMed   Mentions: 10     Fields:    Translation:HumansAnimals
    9. Strengthening Management, Community Engagement, and Sustainability of the Subnational Response to Accelerate Malaria Elimination in Namibia. Am J Trop Med Hyg. 2022 Apr 11. Chung AM, Love E, Neidel J, Mendai I, Nairenge S, van Wyk LA, Rossi S, Larson E, Case P, Gosling J, Viljoen G, Hove M, Agins B, Hamanyela J, Gosling R. PMID: 35405637; PMCID: PMC9209923.
      View in: PubMed   Mentions: 4     Fields:    
    10. Effective management of district-level malaria control and elimination: implementing quality and participative process improvements. BMC Public Health. 2022 01 20; 22(1):140. Agins B, Case P, Chandramohan D, Chen I, Chikodzore R, Chitapi P, Chung A, Gosling R, Gosling J, Gumbi M, Ikeda D, Madinga M, Mnguni P, Murungu J, Gueye CS, Tulloch J, Viljoen G, Leadership and Engagement for improved Accountability and Delivery of Services Framework Development. PMID: 35057789; PMCID: PMC8772105.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    11. Scaling up malaria elimination management and leadership: a pilot in three provinces in Zimbabwe, 2016-2018. Malar J. 2020 May 20; 19(1):185. Chung AM, Case P, Gosling J, Gosling R, Madinga M, Chikodzore R, Hove M, Viljoen G, Chitapi P, Gumbi M, Mnguni P, Murungu J, Dube B, Dhliwayo P, Mberikunashe J. PMID: 32434584; PMCID: PMC7238623.
      View in: PubMed   Mentions: 8     Fields:    Translation:HumansPHPublic Health
    12. District-level approach for tailoring and targeting interventions: a new path for malaria control and elimination. Malar J. 2020 Mar 30; 19(1):125. Gosling R, Chimumbwa J, Uusiku P, Rossi S, Ntuku H, Harvard K, White C, Tatarsky A, Chandramohan D, Chen I. PMID: 32228595; PMCID: PMC7106871.
      View in: PubMed   Mentions: 16     Fields:    Translation:HumansPHPublic Health
    13. Using parasite genetic and human mobility data to infer local and cross-border malaria connectivity in Southern Africa. Elife. 2019 04 02; 8. Tessema S, Wesolowski A, Chen A, Murphy M, Wilheim J, Mupiri AR, Ruktanonchai NW, Alegana VA, Tatem AJ, Tambo M, Didier B, Cohen JM, Bennett A, Sturrock HJ, Gosling R, Hsiang MS, Smith DL, Mumbengegwi DR, Smith JL, Greenhouse B. PMID: 30938286; PMCID: PMC6478435.
      View in: PubMed   Mentions: 72     Fields:    Translation:HumansAnimalsPHPublic Health
    14. Subpatent malaria in a low transmission African setting: a cross-sectional study using rapid diagnostic testing (RDT) and loop-mediated isothermal amplification (LAMP) from Zambezi region, Namibia. Malar J. 2018 Dec 19; 17(1):480. McCreesh P, Mumbengegwi D, Roberts K, Tambo M, Smith J, Whittemore B, Kelly G, Moe C, Murphy M, Chisenga M, Greenhouse B, Ntuku H, Kleinschmidt I, Sturrock H, Uusiku P, Gosling R, Bennett A, Hsiang MS. PMID: 30567537; PMCID: PMC6299963.
      View in: PubMed   Mentions: 20     Fields:    Translation:Humans
    15. Developing an expanded vector control toolbox for malaria elimination. BMJ Glob Health. 2017; 2(2):e000211. Killeen GF, Tatarsky A, Diabate A, Chaccour CJ, Marshall JM, Okumu FO, Brunner S, Newby G, Williams YA, Malone D, Tusting LS, Gosling RD. PMID: 28589022; PMCID: PMC5444090.
      View in: PubMed   Mentions: 76     Fields:    
    16. The central role of national programme management for the achievement of malaria elimination: a cross case-study analysis of nine malaria programmes. Malar J. 2016 Sep 22; 15(1):488. Smith Gueye C, Newby G, Tulloch J, Slutsker L, Tanner M, Gosling RD. PMID: 27659770; PMCID: PMC5034437.
      View in: PubMed   Mentions: 21     Fields:    
    17. Development of a pharmacovigilance safety monitoring tool for the rollout of single low-dose primaquine and artemether-lumefantrine to treat Plasmodium falciparum infections in Swaziland: a pilot study. Malar J. 2016 07 22; 15(1):384. Poirot E, Soble A, Ntshalintshali N, Mwandemele A, Mkhonta N, Malambe C, Vilakati S, Pan S, Darteh S, Maphalala G, Brown J, Hwang J, Pace C, Stergachis A, Vittinghoff E, Kunene S, Gosling R. PMID: 27450652; PMCID: PMC4957931.
      View in: PubMed   Mentions: 15     Fields:    Translation:Humans
    18. Primaquine to reduce transmission of Plasmodium falciparum malaria in Mali: a single-blind, dose-ranging, adaptive randomised phase 2 trial. Lancet Infect Dis. 2016 Jun; 16(6):674-684. Dicko A, Brown JM, Diawara H, Baber I, Mahamar A, Soumare HM, Sanogo K, Koita F, Keita S, Traore SF, Chen I, Poirot E, Hwang J, McCulloch C, Lanke K, Pett H, Niemi M, Nosten F, Bousema T, Gosling R. PMID: 26906747; PMCID: PMC10583596.
      View in: PubMed   Mentions: 71     Fields:    Translation:HumansAnimalsCTClinical Trials
    19. Strategies and approaches to vector control in nine malaria-eliminating countries: a cross-case study analysis. Malar J. 2016 Jan 04; 15:2. Smith Gueye C, Newby G, Gosling RD, Whittaker MA, Chandramohan D, Slutsker L, Tanner M. PMID: 26727923; PMCID: PMC4700736.
      View in: PubMed   Mentions: 25     Fields:    Translation:HumansAnimalsPHPublic Health
    20. Risks of Hemolysis in Glucose-6-Phosphate Dehydrogenase Deficient Infants Exposed to Chlorproguanil-Dapsone, Mefloquine and Sulfadoxine-Pyrimethamine as Part of Intermittent Presumptive Treatment of Malaria in Infants. PLoS One. 2015; 10(11):e0142414. Poirot E, Vittinghoff E, Ishengoma D, Alifrangis M, Carneiro I, Hashim R, Baraka V, Mosha J, Gesase S, Chandramohan D, Gosling R. PMID: 26599634; PMCID: PMC4658078.
      View in: PubMed   Mentions: 6     Fields:    Translation:Humans
    21. An assessment of the supply, programmatic use, and regulatory issues of single low-dose primaquine as a Plasmodium falciparum gametocytocide for sub-Saharan Africa. Malar J. 2015 May 15; 14:204. Chen I, Poirot E, Newman M, Kandula D, Shah R, Hwang J, Cohen JM, Gosling R, Rooney L. PMID: 25971688; PMCID: PMC4446184.
      View in: PubMed   Mentions: 22     Fields:    Translation:HumansAnimals
    22. The independent effect of living in malaria hotspots on future malaria infection: an observational study from Misungwi, Tanzania. Malar J. 2014 Nov 21; 13:445. Mosha JF, Sturrock HJ, Brown JM, Hashim R, Kibiki G, Chandramohan D, Gosling RD. PMID: 25413016; PMCID: PMC4255924.
      View in: PubMed   Mentions: 15     Fields:    Translation:Humans
    23. Fine-scale malaria risk mapping from routine aggregated case data. Malar J. 2014 Nov 03; 13:421. Sturrock HJ, Cohen JM, Keil P, Tatem AJ, Le Menach A, Ntshalintshali NE, Hsiang MS, Gosling RD. PMID: 25366929; PMCID: PMC4349235.
      View in: PubMed   Mentions: 36     Fields:    Translation:Humans
    24. Hot spot or not: a comparison of spatial statistical methods to predict prospective malaria infections. Malar J. 2014 Feb 11; 13:53. Mosha JF, Sturrock HJ, Greenwood B, Sutherland CJ, Gadalla NB, Atwal S, Hemelaar S, Brown JM, Drakeley C, Kibiki G, Bousema T, Chandramohan D, Gosling RD. PMID: 24517452; PMCID: PMC3932034.
      View in: PubMed   Mentions: 38     Fields:    Translation:HumansAnimals
    25. Targeting imported malaria through social networks: a potential strategy for malaria elimination in Swaziland. Malar J. 2013 Jun 27; 12:219. Koita K, Novotny J, Kunene S, Zulu Z, Ntshalintshali N, Gandhi M, Gosling R. PMID: 23805843; PMCID: PMC3710236.
      View in: PubMed   Mentions: 20     Fields:    Translation:HumansPHPublic Health
    26. The economic benefits of malaria elimination: do they include increases in tourism? Malar J. 2012 Jul 28; 11:244. Modrek S, Liu J, Gosling R, Feachem RG. PMID: 22839351; PMCID: PMC3470964.
      View in: PubMed   Mentions: 8     Fields:    Translation:HumansPHPublic Health
    27. IgG responses to Anopheles gambiae salivary antigen gSG6 detect variation in exposure to malaria vectors and disease risk. PLoS One. 2012; 7(6):e40170. Stone W, Bousema T, Jones S, Gesase S, Hashim R, Gosling R, Carneiro I, Chandramohan D, Theander T, Ronca R, Modiano D, Arcà B, Drakeley C. PMID: 22768250; PMCID: PMC3387013.
      View in: PubMed   Mentions: 40     Fields:    Translation:HumansAnimalsPHPublic Health
    28. Hitting hotspots: spatial targeting of malaria for control and elimination. PLoS Med. 2012 Jan; 9(1):e1001165. Bousema T, Griffin JT, Sauerwein RW, Smith DL, Churcher TS, Takken W, Ghani A, Drakeley C, Gosling R. PMID: 22303287; PMCID: PMC3269430.
      View in: PubMed   Mentions: 370     Fields:    Translation:HumansPHPublic Health
    29. Malaria control in Bhutan: case study of a country embarking on elimination. Malar J. 2012 Jan 09; 11:9. Yangzom T, Gueye CS, Namgay R, Galappaththy GN, Thimasarn K, Gosling R, Murugasampillay S, Dev V. PMID: 22230355; PMCID: PMC3278342.
      View in: PubMed   Mentions: 35     Fields:    Translation:HumansAnimalsPHPublic Health
    30. A national policy for malaria elimination in Swaziland: a first for sub-Saharan Africa. Malar J. 2011 Oct 21; 10:313. Kunene S, Phillips AA, Gosling RD, Kandula D, Novotny JM. PMID: 22018266; PMCID: PMC3219738.
      View in: PubMed   Mentions: 25     Fields:    Translation:HumansPHPublic Health
    31. The role of antimalarial treatment in the elimination of malaria. Clin Microbiol Infect. 2011 Nov; 17(11):1617-23. Gosling RD, Okell L, Mosha J, Chandramohan D. PMID: 21951597.
      View in: PubMed   Mentions: 35     Fields:    Translation:HumansAnimalsPHPublic Health
    32. A cluster-randomized trial of mass drug administration with a gametocytocidal drug combination to interrupt malaria transmission in a low endemic area in Tanzania. Malar J. 2011 Aug 24; 10:247. Shekalaghe SA, Drakeley C, van den Bosch S, ter Braak R, van den Bijllaardt W, Mwanziva C, Semvua S, Masokoto A, Mosha F, Teelen K, Hermsen R, Okell L, Gosling R, Sauerwein R, Bousema T. PMID: 21864343; PMCID: PMC3169516.
      View in: PubMed   Mentions: 49     Fields:    Translation:HumansPHPublic Health
    33. Adjusting for heterogeneity of malaria transmission in longitudinal studies. J Infect Dis. 2011 Jul 01; 204(1):1-3. Bousema T, Kreuels B, Gosling R. PMID: 21628650; PMCID: PMC3307167.
      View in: PubMed   Mentions: 19     Fields:    Translation:Humans
    34. Modelling the protective efficacy of alternative delivery schedules for intermittent preventive treatment of malaria in infants and children. PLoS One. 2011 Apr 20; 6(4):e18947. Cairns M, Ghani A, Okell L, Gosling R, Carneiro I, Anto F, Asoala V, Owusu-Agyei S, Greenwood B, Chandramohan D, Milligan P. PMID: 21533088; PMCID: PMC3080380.
      View in: PubMed   Mentions: 9     Fields:    Translation:Humans
    35. Protective efficacy of intermittent preventive treatment of malaria in infants (IPTi) using sulfadoxine-pyrimethamine and parasite resistance. PLoS One. 2010 Sep 07; 5(9):e12618. Griffin JT, Cairns M, Ghani AC, Roper C, Schellenberg D, Carneiro I, Newman RD, Grobusch MP, Greenwood B, Chandramohan D, Gosling RD. PMID: 20838642; PMCID: PMC2935388.
      View in: PubMed   Mentions: 33     Fields:    Translation:HumansAnimals
    36. The cost-effectiveness of intermittent preventive treatment for malaria in infants in Sub-Saharan Africa. PLoS One. 2010 Jun 15; 5(6):e10313. Conteh L, Sicuri E, Manzi F, Hutton G, Obonyo B, Tediosi F, Biao P, Masika P, Matovu F, Otieno P, Gosling RD, Hamel M, Odhiambo FO, Grobusch MP, Kremsner PG, Chandramohan D, Aponte JJ, Egan A, Schellenberg D, Macete E, Slutsker L, Newman RD, Alonso P, Menéndez C, Tanner M. PMID: 20559558; PMCID: PMC2886103.
      View in: PubMed   Mentions: 36     Fields:    Translation:Humans
    37. Identification of hot spots of malaria transmission for targeted malaria control. J Infect Dis. 2010 Jun 01; 201(11):1764-74. Bousema T, Drakeley C, Gesase S, Hashim R, Magesa S, Mosha F, Otieno S, Carneiro I, Cox J, Msuya E, Kleinschmidt I, Maxwell C, Greenwood B, Riley E, Sauerwein R, Chandramohan D, Gosling R. PMID: 20415536.
      View in: PubMed   Mentions: 207     Fields:    Translation:HumansAnimals
    38. Intermittent preventive treatment against malaria: an update. Expert Rev Anti Infect Ther. 2010 May; 8(5):589-606. Gosling RD, Cairns ME, Chico RM, Chandramohan D. PMID: 20455687.
      View in: PubMed   Mentions: 35     Fields:    Translation:HumansAnimals
    39. Duration of protection against clinical malaria provided by three regimens of intermittent preventive treatment in Tanzanian infants. PLoS One. 2010 Mar 01; 5(3):e9467. Cairns M, Gosling R, Carneiro I, Gesase S, Mosha JF, Hashim R, Kaur H, Lemnge M, Mosha FW, Greenwood B, Chandramohan D. PMID: 20209126; PMCID: PMC2830887.
      View in: PubMed   Mentions: 19     Fields:    Translation:Humans
    40. Cost implications of improving malaria diagnosis: findings from north-eastern Tanzania. PLoS One. 2010 Jan 14; 5(1):e8707. Mosha JF, Conteh L, Tediosi F, Gesase S, Bruce J, Chandramohan D, Gosling R. PMID: 20090933; PMCID: PMC2806838.
      View in: PubMed   Mentions: 22     Fields:    Translation:Humans
    41. An unusual case of meningococcal meningitis complicated with subdural empyema in a 3 month old infant: a case report. Cases J. 2009 Sep 17; 2:6335. Yip K, Gosling RD, Jones V, Hosein IK. PMID: 20181146; PMCID: PMC2827145.
      View in: PubMed   Mentions:
    42. Protective efficacy and safety of three antimalarial regimens for intermittent preventive treatment for malaria in infants: a randomised, double-blind, placebo-controlled trial. Lancet. 2009 Oct 31; 374(9700):1521-32. Gosling RD, Gesase S, Mosha JF, Carneiro I, Hashim R, Lemnge M, Mosha FW, Greenwood B, Chandramohan D. PMID: 19765815.
      View in: PubMed   Mentions: 56     Fields:    Translation:Humans
    43. Mode of action and choice of antimalarial drugs for intermittent preventive treatment in infants. Trans R Soc Trop Med Hyg. 2009 Dec; 103(12):1199-201. Cairns M, Gosling R, Gesase S, Mosha J, Greenwood B, Chandramohan D. PMID: 19740503; PMCID: PMC3787296.
      View in: PubMed   Mentions: 6     Fields:    Translation:Humans
    44. Community response to intermittent preventive treatment of malaria in infants (IPTi) delivered through the expanded programme of immunization in five African settings. Malar J. 2009 Aug 10; 8:191. Gysels M, Pell C, Mathanga DP, Adongo P, Odhiambo F, Gosling R, Akweongo P, Mwangi R, Okello G, Mangesho P, Slutsker L, Kremsner PG, Grobusch MP, Hamel MJ, Newman RD, Pool R. PMID: 19664250; PMCID: PMC2734860.
      View in: PubMed   Mentions: 25     Fields:    Translation:Humans
    45. Rapid assessment of malaria transmission using age-specific sero-conversion rates. PLoS One. 2009 Jun 29; 4(6):e6083. Stewart L, Gosling R, Griffin J, Gesase S, Campo J, Hashim R, Masika P, Mosha J, Bousema T, Shekalaghe S, Cook J, Corran P, Ghani A, Riley EM, Drakeley C. PMID: 19562032; PMCID: PMC2698122.
      View in: PubMed   Mentions: 129     Fields:    Translation:HumansAnimals
    46. Intermittent preventive treatment of malaria in infants: how does it work and where will it work? Trop Med Int Health. 2009 Sep; 14(9):1003-10. Gosling RD, Carneiro I, Chandramohan D. PMID: 19558374.
      View in: PubMed   Mentions: 8     Fields:    Translation:Humans
    47. RTS,S/AS01E vaccine against malaria. N Engl J Med. 2009 Mar 19; 360(12):1253; author reply 1253-4. Gosling RD, Chandramohan D. PMID: 19297579.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    48. High resistance of Plasmodium falciparum to sulphadoxine/pyrimethamine in northern Tanzania and the emergence of dhps resistance mutation at Codon 581. PLoS One. 2009; 4(2):e4569. Gesase S, Gosling RD, Hashim R, Ord R, Naidoo I, Madebe R, Mosha JF, Joho A, Mandia V, Mrema H, Mapunda E, Savael Z, Lemnge M, Mosha FW, Greenwood B, Roper C, Chandramohan D. PMID: 19238219; PMCID: PMC2644264.
      View in: PubMed   Mentions: 101     Fields:    Translation:HumansAnimals
    49. Placental malaria increases malaria risk in the first 30 months of life: not causal. Clin Infect Dis. 2009 Feb 15; 48(4):497-8; author reply 498-9. Cairns M, Gosling R, Chandramohan D. PMID: 19586381.
      View in: PubMed   Mentions: 6     Fields:    Translation:HumansPHPublic Health
    50. Loss of population levels of immunity to malaria as a result of exposure-reducing interventions: consequences for interpretation of disease trends. PLoS One. 2009; 4(2):e4383. Ghani AC, Sutherland CJ, Riley EM, Drakeley CJ, Griffin JT, Gosling RD, Filipe JA. PMID: 19198649; PMCID: PMC2634959.
      View in: PubMed   Mentions: 59     Fields:    Translation:HumansPHPublic Health
    51. Overuse of artemisinin-combination therapy in Mto wa Mbu (river of mosquitoes), an area misinterpreted as high endemic for malaria. Malar J. 2008 Nov 05; 7:232. Mwanziva C, Shekalaghe S, Ndaro A, Mengerink B, Megiroo S, Mosha F, Sauerwein R, Drakeley C, Gosling R, Bousema T. PMID: 18986520; PMCID: PMC2588630.
      View in: PubMed   Mentions: 34     Fields:    Translation:HumansAnimalsPHPublic Health
    52. Tackling malaria today: Beware resurgence of malaria where incidence has fallen. BMJ. 2008 Sep 10; 337:a1592. Gosling RD, Chandramohan D. PMID: 18784170.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    53. Presumptive treatment of fever cases as malaria: help or hindrance for malaria control? Malar J. 2008 Jul 16; 7:132. Gosling RD, Drakeley CJ, Mwita A, Chandramohan D. PMID: 18631377; PMCID: PMC2488354.
      View in: PubMed   Mentions: 22     Fields:    
    54. Asymptomatic malaria associated with protection: not causal. Clin Infect Dis. 2008 Jul 01; 47(1):147; author reply 147-8. Gosling RD. PMID: 18522513.
      View in: PubMed   Mentions: 3     Fields:    Translation:HumansAnimals
    55. Duration of protection against malaria and anaemia provided by intermittent preventive treatment in infants in Navrongo, Ghana. PLoS One. 2008 May 21; 3(5):e2227. Cairns M, Carneiro I, Milligan P, Owusu-Agyei S, Awine T, Gosling R, Greenwood B, Chandramohan D. PMID: 18493597; PMCID: PMC2375060.
      View in: PubMed   Mentions: 31     Fields:    Translation:Humans
    56. Can changes in malaria transmission intensity explain prolonged protection and contribute to high protective efficacy of intermittent preventive treatment for malaria in infants? Malar J. 2008 Apr 03; 7:54. Gosling RD, Ghani AC, Deen JL, von Seidlein L, Greenwood BM, Chandramohan D. PMID: 18387180; PMCID: PMC2323384.
      View in: PubMed   Mentions: 13     Fields:    Translation:Humans
    57. Effective malaria control: better burden estimates needed. Lancet. 2008 Mar 01; 371(9614):724. Gosling RD, Drakeley CJ, Chandramohan D. PMID: 18313500.
      View in: PubMed   Mentions: 2     Fields:    Translation:HumansPHPublic Health
    58. Implications of attempts to eliminate malaria for front-line clinicians. Trop Doct. 2008 Jan; 38(1):1-2. Whitty C, Gosling R. PMID: 18302847.
      View in: PubMed   Mentions: 1     Fields:    Translation:HumansPHPublic Health
    59. Intermittent preventive therapy for malaria: progress and future directions. Curr Opin Infect Dis. 2007 Dec; 20(6):613-20. Grobusch MP, Egan A, Gosling RD, Newman RD. PMID: 17975412.
      View in: PubMed   Mentions: 21     Fields:    Translation:Humans
    60. Primaquine clears submicroscopic Plasmodium falciparum gametocytes that persist after treatment with sulphadoxine-pyrimethamine and artesunate. PLoS One. 2007 Oct 10; 2(10):e1023. Shekalaghe S, Drakeley C, Gosling R, Ndaro A, van Meegeren M, Enevold A, Alifrangis M, Mosha F, Sauerwein R, Bousema T. PMID: 17925871; PMCID: PMC1995753.
      View in: PubMed   Mentions: 76     Fields:    Translation:HumansAnimals
    61. Over-diagnosis of malaria is not a lost cause. Malar J. 2006 Dec 13; 5:120. Masika PM, Semarundu WJ, Urassa R, Mosha J, Chandramohan D, Gosling RD. PMID: 17166271; PMCID: PMC1712345.
      View in: PubMed   Mentions: 9     Fields:    Translation:Humans
    62. Single-dose sulfadoxine-pyrimethamine in intermittent preventive treatment of malaria. J Infect Dis. 2006 Jun 01; 193(11):1609-10; author reply 1610-1. Gosling RD, Schellenberg DM, Chandramohan D. PMID: 16652293.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    63. Prevalences of Pneumocystis jiroveci, Mycobacterium tuberculosis and Streptococcus pneumoniae infection in children with severe pneumonia, in a tertiary referral hospital in northern Tanzania. Ann Trop Med Parasitol. 2006 Apr; 100(3):245-9. Uriyo J, Gosling RD, Maddox V, Sam NE, Schimana W, Gillespie SH, McHugh TD. PMID: 16630382.
      View in: PubMed   Mentions: 4     Fields:    Translation:HumansAnimals
    64. Early bactericidal activity of a moxifloxacin and isoniazid combination in smear-positive pulmonary tuberculosis. J Antimicrob Chemother. 2005 Dec; 56(6):1169-71. Gillespie SH, Gosling RD, Uiso L, Sam NE, Kanduma EG, McHugh TD. PMID: 16223939.
      View in: PubMed   Mentions: 9     Fields:    Translation:HumansCells
    65. Malaria diagnosis and treatment: one size does not fit all. PLoS Med. 2005 Jun; 2(6):e156; author reply e165. Drakeley C, Gosling R, Reyburn H. PMID: 15971939; PMCID: PMC1160571.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    66. Mycobacterium tuberculosis lineage: a naming of the parts. Tuberculosis (Edinb). 2005 May; 85(3):127-36. McHugh TD, Batt SL, Shorten RJ, Gosling RD, Uiso L, Gillespie SH. PMID: 15850751.
      View in: PubMed   Mentions: 5     Fields:    Translation:HumansCells
    67. Prospective evaluation of BDProbeTec strand displacement amplification (SDA) system for diagnosis of tuberculosis in non-respiratory and respiratory samples. J Med Microbiol. 2004 Dec; 53(Pt 12):1215-1219. McHugh TD, Pope CF, Ling CL, Patel S, Billington OJ, Gosling RD, Lipman MC, Gillespie SH. PMID: 15585500.
      View in: PubMed   Mentions: 14     Fields:    Translation:HumansCells
    68. The bactericidal activity of moxifloxacin in patients with pulmonary tuberculosis. Am J Respir Crit Care Med. 2003 Dec 01; 168(11):1342-5. Gosling RD, Uiso LO, Sam NE, Bongard E, Kanduma EG, Nyindo M, Morris RW, Gillespie SH. PMID: 12917230.
      View in: PubMed   Mentions: 46     Fields:    Translation:HumansCellsCTClinical Trials
    69. A multicentre comparison of a novel surrogate marker for determining the specific potency of anti-tuberculosis drugs. J Antimicrob Chemother. 2003 Sep; 52(3):473-6. Gosling RD, Heifets L, Gillespie SH. PMID: 12888596.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    70. A reiterative method for calculating the early bactericidal activity of antituberculosis drugs. Am J Respir Crit Care Med. 2002 Jul 01; 166(1):31-5. Gillespie SH, Gosling RD, Charalambous BM. PMID: 12091167.
      View in: PubMed   Mentions: 14     Fields:    Translation:HumansCells
    Roly's Networks
    Concepts (232)
    Derived automatically from this person's publications.
    Explore
    _
    Co-Authors (19)
    People in Profiles who have published with this person.
    Explore
    _
    Similar People (60)
    People who share similar concepts with this person.
    Explore
    _
    Same Department
    Search Department
    _

    UCSF Profiles is managed by the UCSF Clinical and Translational Science Institute (CTSI), part of the Clinical and Translational Science Award program funded by the National Center for Advancing Translational Sciences (Grant Number UL1 TR000004) at the National Institutes of Health (NIH).

    We use cookies to operate our website. We also use cookies to analyze our site’s performance and improve your experience on our site. For more information about how we use cookies, please see our Website Terms of Use. This site is running Profiles RNS version UCSF-v3.1.0-21-g9d46e6c4 on PROFILES-PWEB04.

    Copyright © The Regents of the University of California.